Evolus expanded its partnership with Symatese to gain exclusive rights to commercialize the Estyme injectable HA gel collection in Canada, Australia, and New Zealand, realizing a consistent multi-product platform alongside Jeuveau. This strategic expansion strengthens its international competitive positioning to address a combined $500 million market opportunity.